KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Current Assets: 2015-2025

Historic Current Assets for CRISPR Therapeutics AG (CRSP) over the last 9 years, with Sep 2025 value amounting to $1.9 billion.

  • CRISPR Therapeutics AG's Current Assets fell 0.76% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year decrease of 0.76%. This contributed to the annual value of $1.9 billion for FY2024, which is 1.52% up from last year.
  • According to the latest figures from Q3 2025, CRISPR Therapeutics AG's Current Assets is $1.9 billion, which was up 11.27% from $1.7 billion recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Current Assets peaked at $2.6 billion during Q2 2021, and registered a low of $1.7 billion during Q2 2025.
  • Its 3-year average for Current Assets is $1.9 billion, with a median of $1.9 billion in 2023.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Current Assets spiked by 171.43% in 2021, and later fell by 23.35% in 2022.
  • Quarterly analysis of 5 years shows CRISPR Therapeutics AG's Current Assets stood at $2.4 billion in 2021, then dropped by 23.35% to $1.9 billion in 2022, then grew by 2.97% to $1.9 billion in 2023, then rose by 1.52% to $1.9 billion in 2024, then declined by 0.76% to $1.9 billion in 2025.
  • Its Current Assets stands at $1.9 billion for Q3 2025, versus $1.7 billion for Q2 2025 and $1.9 billion for Q1 2025.